Gala Pharmaceutical, Inc. (GLPH) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
18881 VON KARMAN AVE. IRVINE, CA 92612 |
| State of Incorp. | NV |
| Fiscal Year End | November 30 |
| Industry (SIC) | 23 - Apparel And Other Finished Products Made From Fabrics And Similar Materials (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 5/31/2019 Q2 | 2/28/2019 Q1 | 11/30/2018 Q4 | 8/31/2018 Q3 | 5/31/2018 Q2 | 2/28/2018 Q1 | 11/30/2017 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 216 | 158 | 82 | 39 | 0 | 8 | |||
| Cash and cash equivalents | 179 | 116 | 15 | 39 | 0 | 8 | |||
| Short-term investments | 37 | 42 | 68 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 2 | 2 | 2 | 2 | |||||
| Inventory | 2 | 2 | 2 | 2 | |||||
| Prepaid expense | 27 | 69 | 115 | 174 | 265 | 42 | |||
| Other undisclosed current assets | 10 | 10 | 10 | 10 | |||||
| Total current assets: | 243 | 227 | 210 | 225 | 278 | 62 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 39 | 35 | 38 | 41 | 43 | 46 | |||
| Total noncurrent assets: | 39 | 35 | 38 | 41 | 43 | 46 | |||
| TOTAL ASSETS: | 283 | 262 | 248 | 266 | 321 | 108 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 97 | 82 | 62 | 61 | 41 | 35 | |||
| Settlement liabilities | 64 | 64 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 33 | 18 | 62 | 61 | 41 | 35 | |||
| Debt | 282 | 279 | 287 | 287 | 374 | ||||
| Derivative instruments and hedges, liabilities | 833 | 391 | 391 | 453 | |||||
| Due to related parties | 123 | 123 | 123 | 48 | |||||
| Total current liabilities: | 379 | 82 | 1,297 | 863 | 843 | 910 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 1,254 | 1,039 | 158 | 105 | 112 | 103 | |||
| Total liabilities: | 1,633 | 1,121 | 1,455 | 967 | 956 | 1,014 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,281) | (811) | (1,198) | (697) | (635) | (906) | |||
| Preferred stock | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Common stock | 95 | 92 | 59 | 57 | 48 | 36 | |||
| Common stock, value, subscriptions | |||||||||
| Additional paid in capital | 4,353 | 4,291 | 3,637 | 3,492 | 3,164 | 2,417 | |||
| Deferred compensation equity | (74) | (117) | (125) | (51) | (45) | (166) | |||
| Accumulated deficit | (5,655) | (5,077) | (4,907) | (4,196) | (3,802) | (3,219) | |||
| Warrants and rights outstanding | 6 | ||||||||
| Other undisclosed equity, attributable to parent | 132 | 25 | |||||||
| Equity, attributable to noncontrolling interest | (70) | (47) | (10) | (4) | |||||
| Other undisclosed equity | |||||||||
| Total equity: | (1,350) | (859) | (1,208) | (702) | (635) | (906) | |||
| TOTAL LIABILITIES AND EQUITY: | 283 | 262 | 248 | 266 | 321 | 108 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 5/31/2019 Q2 | 2/28/2019 Q1 | 11/30/2018 Q4 | 8/31/2018 Q3 | 5/31/2018 Q2 | 2/28/2018 Q1 | 11/30/2017 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 5 | |||||||
| Cost of revenue | (3) | (50) | ||||||
| Gross profit: | 1 | (50) | ||||||
| Operating expenses | (231) | (477) | (309) | (384) | (548) | (381) | ||
| Operating loss: | (231) | (477) | (309) | (383) | (548) | (431) | ||
| Nonoperating income (expense) | (369) | 269 | (408) | (15) | (35) | (501) | ||
| Investment income, nonoperating | 72 | |||||||
| Interest and debt expense | 17 | 34 | 24 | (16) | 95 | |||
| Loss from continuing operations: | (583) | (174) | (693) | (414) | (488) | (932) | ||
| Loss before gain (loss) on sale of properties: | (583) | (174) | (693) | (414) | (488) | (932) | ||
| Other undisclosed net income (loss) | (17) | (34) | (24) | 16 | ||||
| Net loss: | (599) | (208) | (717) | (398) | (488) | (932) | ||
| Net income attributable to noncontrolling interest | 22 | 38 | 5 | 4 | ||||
| Other undisclosed net income (loss) attributable to parent | (95) | 50 | ||||||
| Net loss available to common stockholders, diluted: | (577) | (170) | (712) | (394) | (583) | (882) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 5/31/2019 Q2 | 2/28/2019 Q1 | 11/30/2018 Q4 | 8/31/2018 Q3 | 5/31/2018 Q2 | 2/28/2018 Q1 | 11/30/2017 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (599) | (208) | (717) | (398) | (488) | (932) | ||
| Comprehensive loss: | (599) | (208) | (717) | (398) | (488) | (932) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 22 | 38 | 5 | 4 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (577) | (170) | (712) | (394) | (488) | (932) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.